An aqueous composition including (a) metal ions including tin ions and silver ions and (b) at least one complexing agent of formula C11

R.sup.C12-X.sup.C11-R.sup.C11 (C11)

and their salts, where X.sup.C11 is selected from (a) a divalent 5 or 6 membered aromatic N-heterocyclic group; (b) a divalent 6 membered aromatic carbocyclic group; and (c) a divalent 5 or 6 membered aliphatic N-heterocyclic group including one N atom and optionally a second heteroatom selected from N and O; all of which may be unsubstituted or substituted by one or more OH or one or more R.sup.C14; R.sup.C11 is selected from

##STR00001## ; and R.sup.C12 is selected from R.sup.C11, X.sup.C11-R.sup.C11, H, OH, NR.sup.C14.sub.2, C.sub.1 to C.sub.10 alkyl, and C.sub.1 to C.sub.10 alkoxy

Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia. ##STR00001##

Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia. ##STR00001##

A compound, represented by the following formula or a medically acceptable salt thereof, having an effect of regulating the activity of an androgen receptor. In the formula, X represents S, O; Z represents (R.sup.a).sub.n-A- (CR.sup.13R.sup.14).sub.0-1(CR.sup.11R.sup.12).sub.0-1; A represents aryl, heteroaryl; R.sup.1 represents alkyl, cycloalkyl, alkenyl, alkynyl, alkoxyalkyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl; R.sup.2 represents hydrogen, halogen, alkyl, cycloalkyl, phenyl; R3 represents hydrogen, halogen, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkenyl, aryl, arylalkyl, heterocycle, heterocyclic alkyl, acyl, cycloalkylcarbonyl, benzoyl, spiroalkyl, adamantyl, silyl, R.sup.31R.sup.32NCO; R.sup.4 and R.sup.5 represent hydrogen, halogen, alkyl, phenyl, and cycloalkyl.

##STR00001##

A compound, or a protonate or salt thereof, having a formula I of: wherein Y represents an optionally substituted aromatic group; n is 1 or 2; a is 0 to 4; R.sup.1 and R.sup.2 are each independently H; optionally substituted alkyl; optionally substituted aralkyl; acyl; phosphonyl; SO.sub.2R.sup.12; C(O)R.sup.13; C(O)OR.sup.14; C(O)NR.sup.15R.sup.16; C(O)CH.sub.2R.sup.17; or C(S)NR.sup.18R.sup.19; S(O)R20; or SO.sub.2NR.sup.21R.sup.22, wherein R.sup.12-R.sup.22 are each independently H, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted aryl, or C(O)R.sup.23, wherein R.sup.23 is H, optionally substituted alkyl, optionally substituted aralkyl, or optionally substituted aryl; and each R.sup.3 is independently optionally substituted alkyl, halogen, optionally substituted alkoxy, optionally substituted carboxyl, amide; amino; or nitro.

A compound, or a protonate or salt thereof, having a formula I of: wherein Y represents an optionally substituted aromatic group; n is 1 or 2; a is 0 to 4; R.sup.1 and R.sup.2 are each independently H; optionally substituted alkyl; optionally substituted aralkyl; acyl; phosphonyl; SO.sub.2R.sup.12; C(O)R.sup.13; C(O)OR.sup.14; C(O)NR.sup.15R.sup.16; C(O)CH.sub.2R.sup.17; or C(S)NR.sup.18R.sup.19; S(O)R20; or SO.sub.2NR.sup.21R.sup.22, wherein R.sup.12-R.sup.22 are each independently H, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted aryl, or C(O)R.sup.23, wherein R.sup.23 is H, optionally substituted alkyl, optionally substituted aralkyl, or optionally substituted aryl; and each R.sup.3 is independently optionally substituted alkyl, halogen, optionally substituted alkoxy, optionally substituted carboxyl, amide; amino; or nitro.

A compound, or a protonate or salt thereof, having a formula I of: wherein Y represents an optionally substituted aromatic group; n is 1 or 2; a is 0 to 4; R.sup.1 and R.sup.2 are each independently H; optionally substituted alkyl; optionally substituted aralkyl; acyl; phosphonyl; S0.sub.2R.sup.12; C(0)R.sup.13; C(0)OR.sup.14; C(0)NR.sup.15R.sup.16; C(0)CH.sub.2R.sup.17; or C(S)NR.sup.18R.sup.19; S(0)R20; or S0.sub.2NR.sup.21R.sup.22, wherein R.sup.12-R.sup.22 are each independently H, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted aryl, or C(0)R.sup.23, wherein R.sup.23 is H, optionally substituted alkyl, optionally substituted aralkyl, or optionally substituted aryl; and each R.sup.3 is independently optionally substituted alkyl, halogen, optionally substituted alkoxy, optionally substituted carboxyl, amide; amino; or nitro.

A compound, or a protonate or salt thereof, having a formula I of: wherein Y represents an optionally substituted aromatic group; n is 1 or 2; a is 0 to 4; R.sup.1 and R.sup.2 are each independently H; optionally substituted alkyl; optionally substituted aralkyl; acyl; phosphonyl; S0.sub.2R.sup.12; C(0)R.sup.13; C(0)OR.sup.14; C(0)NR.sup.15R.sup.16; C(0)CH.sub.2R.sup.17; or C(S)NR.sup.18R.sup.19; S(0)R20; or S0.sub.2NR.sup.21R.sup.22, wherein R.sup.12-R.sup.22 are each independently H, optionally substituted alkyl, optionally substituted aralkyl, optionally substituted aryl, or C(0)R.sup.23, wherein R.sup.23 is H, optionally substituted alkyl, optionally substituted aralkyl, or optionally substituted aryl; and each R.sup.3 is independently optionally substituted alkyl, halogen, optionally substituted alkoxy, optionally substituted carboxyl, amide; amino; or nitro.

Spirocyclic compounds, including chiral spiro diamine, chiral spiro amino naphthol, chiral spiro bis(indole), chiral spiro diaryl diol, chiral spiro diaryl diamine, chiral spiro amino naphthol, chiral spiro diaryl diindole, and chiral spiro phospholane useful as chiral ligands and chiral organocatalysts and methods of preparation and methods of use thereof. Owing to the molecular shape and three-dimensional orientation, the chiral diamine and chiral amino naphthol molecules provide a skeleton for use as ligands and organocatalysts.

Spirocyclic compounds, including chiral spiro diamine, chiral spiro amino naphthol, chiral spiro bis(indole), chiral spiro diaryl diol, chiral spiro diaryl diamine, chiral spiro amino naphthol, chiral spiro diaryl diindole, and chiral spiro phospholane useful as chiral ligands and chiral organocatalysts and methods of preparation and methods of use thereof. Owing to the molecular shape and three-dimensional orientation, the chiral diamine and chiral amino naphthol molecules provide a skeleton for use as ligands and organocatalysts.